(1) Improve knowledge and prognosis of the natural history and indications for treatment, particularly in HBeAg-positive immunotolerant patients and HBeAg-negative patients with serum HBV DNA levels below 20,000 IU/ml.
(1）提高自然历史, 治疗预后 和应当治疗的知识，尤其是HBeAg阳性免疫耐受的患者和HBeAg阴性血清HBV DNA水平低于20,000 IU / ml的患者。
(2) Assess the role of non-invasive markers (serum and biophysical) for the evaluation of the severity of liver disease and for the follow-up of treated and untreated patients.
(2）评估非侵入性标志物（血清和生物物理）在肝脏疾病的严重程度评价和后续处理和未经处理的患者的作用。
(3) Further clarify the role of serum HBsAg levels in the evaluation of the natural history, prediction of therapeutic responses and treatment individualisation.
(3）进一步澄清血清HBsAg水平评价在自然历史，预测治疗反应 和个体化治疗中的作用。
(4) Assess host genetic and viral markers to determine prognosis and optimise patients’ management.
4）评估病人基因的标记和病毒的标记，以确定预后和优化病人的管理。
(5) Assess the impact of early diagnosis and early treatment intervention.
(5）评估早期诊断和早期治疗干预的影响。
(6) Assess long-term safety and resistance to the current firstline NAs (entecavir and tenofovir).
(6）评估当前FIRSTLINE NAS（恩替卡韦和替诺福韦）长期安全性和耐药性。
(7) Identify markers that predict successful NA discontinuation.
(7）识别标记，预测停药成功。
(8) Assess the safety and efficacy of the combination of PEGIFN with a potent NA (entecavir or tenofovir) to increase anti-HBe and anti-HBs seroconversion rates.
(8）评估 PEGIFN + 一个强力的NA（恩替卡韦或替诺福韦）的安全性和有效性的
，以增加抗-HBe和抗-HBs阳转率
(9) Develop and assess new drugs and therapeutic approaches, particularly immunomodulatory therapies, to enhance loss of HBeAg and HBsAg and subsequent seroconversion.
(9）制定和评估新的药物和治疗方法，尤其是免疫疗法，以提高清除HBeAg和HBsAg和随后的血清转换。
(10) Assess long-term impact of therapy on the prevention of cirrhosis and its complications and HCC.
(10）评估治疗的长期影响预防肝硬化和及其并发症肝癌。
(11) Develop strategies and identify subgroups for effective HBIg free prophylaxis after liver transplantation for HBV related liver disease.
(11）制定有效的战略，确定那些病人,可用无乙肝免疫球蛋白预防 在HBV相关的肝脏疾病的肝移植后.
